Clinical Trial Update: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Debio 4126 in participants with acromegaly or functioning gastroenteropancreatic neuroendocrine tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly
• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• Debio 4126

Snippet

Sponsor: Debiopharm International SA | Conditions: Acromegaly, GEP-NET | Phase 1 | Status: TERMINATED